StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The stock has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52.
About Nabriva Therapeutics
Recommended Stories
- Five stocks we like better than Nabriva Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- Oracle Announces Game-Changing News for the AI Industry
- How Can Investors Benefit From After-Hours Trading
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Short a Stock in 5 Easy StepsĀ
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.